Qinyi Xu1,
Jun Liu1,
Dong Wang1,
Yinong Xu3,
Meng Ji3,
Junhui Chen2 
,
Yuhai Wang2
For correspondence:- Junhui Chen Email: chenjunhui1110@126.com
Accepted: 21 June 2018 Published: 28 July 2018
Citation: Xu Q, Liu J, Wang D, Xu Y, Ji M, Chen J, et al. Application of statins in management of glioma: Recent advances. Trop J Pharm Res 2018; 17(7):1445-1451 doi: 10.4314/tjpr.v17i7.31
© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Gliomas are common primary intra-cerebral tumors in adults, and seriously threaten the health and life of affected patients, especially highly-malignant gliomas, such as glioblastoma multiforme. The clinical prognosis of glioma patients is poor, even for those who have received comprehensive treatment including surgery and concurrent chemo- and/or radio-therapy. As a structural analog of β-hydroxy-β-methylglutaryl coenzyme A (HMG CoA) reductase, statins are a restrictive enzyme in the metabolism of cholesterol. Recent laboratory studies and clinical trials have demonstrated that statins can exert anti-tumor effect, improve clinical prognosis and significantly prolong the survival time of glioma patients. This article is aimed to highlight the mechanisms of the anti-glioma effect of statins and review recent advances in the management of the disease.
Archives
News Updates
Fulltext in PDF